SCHEMBL12437201

SCHEMBL12437201

CC(=O)N[C@H]1CC[C@H](n2nnnc2C)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.42
JAK1 P23458 1/20 0.42
PDE7A Q13946 1/20 0.40
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
TOP2A P11388 1/20 0.37
TOP2B Q02880 1/20 0.37
ALDH1A1 P00352 3/20 0.36
GAA P10253 2/20 0.36
RAB9A P51151 1/20 0.36
TSHR P16473 1/20 0.36
SMYD3 Q9H7B4 1/20 0.35
CYP2C9 P11712 1/20 0.35
CCNE1 P24864 1/20 0.35
CDK2 P24941 1/20 0.35
MAPK8 P45983 1/20 0.35
MAPK9 P45984 1/20 0.35
MAPK10 P53779 1/20 0.35
ENPP2 Q13822 1/20 0.35
HSD11B1 P28845 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22722036 0.80 MEN1 (0.41) JAK2JAK1PDE7AMEN1KMT2A
SCHEMBL12436080 0.80 MEN1 (0.38) MEN1KMT2AALDH1A1GAARAB9A
SCHEMBL12436842 0.80 MEN1 (0.38) MEN1KMT2AALDH1A1GAARAB9A
SCHEMBL12435470 0.76 MEN1 (0.40) PDE7AMEN1KMT2AALDH1A1RAB9A
SCHEMBL16400071 0.75 ENPP2 (0.42) MEN1KMT2AALDH1A1RAB9ATSHR
SCHEMBL22113418 0.73 TSHR (0.50) MEN1KMT2AALDH1A1GAARAB9A
SCHEMBL17001650 0.72 ALOX15 (0.45) MEN1KMT2AALDH1A1GAATSHR
SCHEMBL284318 0.70 ATM (0.56) ALDH1A1RAB9A
SCHEMBL50350 0.70
SCHEMBL284319 0.70 ATM (0.56) ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE49686-E1 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-10 US disclosed
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME NTSR2, BDKRB1, AVPR1B JAK2 411/4885JAK1 894/4885PDE7A 3121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.